{"transactions":[{"id":888377,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-02-23T21:00:18.000Z","date":"2026-02-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":6479,"price":16.32,"value":105737.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":232940,"source":{"system":"sec-edgar","filing":"0001140361-26-006460","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036126006460/form4.xml","form_type":"4"}},{"id":1080791,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-07-28T21:00:41.000Z","date":"2025-07-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7123,"price":17.31,"value":123299.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 35,392 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":239419,"source":{"system":"sec-edgar","filing":"0001140361-25-027641","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036125027641/form4.xml","form_type":"4"}},{"id":1099437,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-06-30T21:02:09.000Z","date":"2025-06-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":9838,"price":18.4,"value":181019.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 24,415 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":246542,"source":{"system":"sec-edgar","filing":"0001140361-25-024252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036125024252/form4.xml","form_type":"4"}},{"id":1241168,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-02-27T21:00:21.000Z","date":"2025-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":5280,"price":15.78,"value":83318.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 56,250 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 28,003 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":256380,"source":{"system":"sec-edgar","filing":"0001140361-25-006384","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036125006384/form4.xml","form_type":"4"}},{"id":1253437,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-21T21:01:55.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":93023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan."}],"balance_after":93023,"derivative":{"exercise_price":16.07,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":93023},"source":{"system":"sec-edgar","filing":"0001140361-25-005536","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036125005536/form4.xml","form_type":"4"}},{"id":1253436,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-02-21T21:01:55.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":62227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\"), subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (v) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs."}],"balance_after":261660,"source":{"system":"sec-edgar","filing":"0001140361-25-005536","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036125005536/form4.xml","form_type":"4"}},{"id":1354755,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2024-11-22T21:05:18.000Z","date":"2024-11-22","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":21.15,"value":317250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that were granted on June 26, 2023 and vested on June 26, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs."}],"balance_after":199433,"source":{"system":"sec-edgar","filing":"0001140361-24-047702","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036124047702/form4.xml","form_type":"4"}},{"id":1448203,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-26T21:05:33.000Z","date":"2024-07-24","kind":"grant","planned":false,"acquired":true,"shares":115100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date."}],"balance_after":115100,"derivative":{"exercise_price":13.58,"expiration_date":"2034-07-24","underlying":"Common Stock","underlying_shares":115100},"source":{"system":"sec-edgar","filing":"0001140361-24-034471","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036124034471/form4.xml","form_type":"4"}},{"id":1448202,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":65203,"kind":"person","name":"Tade Brad L.","position":1,"cik":"0002030561","reported_name":"Tade Brad L.","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2024-07-26T21:05:33.000Z","date":"2024-07-24","kind":"grant","planned":false,"acquired":true,"shares":72400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\") subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 75,000 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from Footnote 2 above) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 17,033 shares acquired in open market purchases and pursuant to the vesting of RSUs."}],"balance_after":214433,"source":{"system":"sec-edgar","filing":"0001140361-24-034471","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030561/000114036124034471/form4.xml","form_type":"4"}}]}